72.8 ± 9.1 years, mean ejection fraction 22.5 ± 7.1 %, agreed to undergo this test (Table 1 ). The ECG prior to implantation showed left bundle branch block (LBBB) in 12, non-LBBB in 4, and right ventricular (RV) pacing in 8 patients.
In 23 patients, a 6F multipurpose angioplasty guiding catheter was introduced into the LV after a standard transseptal catheterisation. In one patient, the guiding catheter was introduced through the radial artery following coronary angiography. Through this guiding catheter, endocardial pacing and measurements of LVdP/dtmax were accomplished by roving a Medtronic 6416 temporary bipolar screw-in lead (Medtronic Inc. Minneapolis, MN.) and a RADI pressure wire (RADI Medical, a St Jude Medical Company, St. Paul, MN) inside the LV cavity.
Initially the atrioventricular and interventricular intervals of the implanted system were optimised to obtain the maximal LVdP/dtmax. LV pacing was performed from basal posterolateral, mid-posterolateral, LV apical and LV septal locations, and optimal AHR obtained after optimisation of the CRT system for all positions. If none of the 4 endocardial positions were opposite the position of the coronary sinus lead, an additional measurement was done at this location. A rise in LVdP/dtmax ≥ 15 % from baseline was considered to be a positive haemodynamic response.
In all patients with an AHR of ≥ 15 % during LV endocardial pacing, the interval between the onset of the QRS complex and the intrinsic activation at the LV electrode (Q-LV interval) was measured and the ratio between Q-LV/QRS width interval calculated. This ratio expresses the relation between Q-LV interval and QRS width, which is a better indicator for late or early LV sensing than the absolute value of Q-LV.
Results

Acute haemodynamic response of the total study population
Notwithstanding that all patients were clinical non-responders, in 5 patients LVdP/dtmax with the implanted coronary sinus system increased ≥ 15 % after optimisation: average 30.2 %, 15.6-44.5 % (Table 2 ). In 3 out of these 5 patients with the coronary sinus lead in a posterolateral position, endocardial pacing did not increase the LVdP/dtmax substantially (AHR less than 3 % and even an adverse effect from LV endocardial pacing was observed in one patient). In one of the two remaining patients with an apical posi- M  56  IV  DCM  13  LBBB  135  Pt. 02  M  78  III-IV  ICM  17  RVP  225  Pt. 03  M  75  III  ICM  12  LBBB  174  Pt. 04  M  70  III  ICM  19  RVP  196  Pt. 05  M  81  II-III  ICM  26  LBBB  165  Pt. 06  M  79  III  ICM  18  Non-LBBB  170  Pt. 07  M  74  III-IV  ICM  28  Non-LBBB  175  Pt. 08  M  87  III  ICM  42  LBBB  154  Pt. 09  M  79  III-IV  ICM  14 169 ms (135-198 ms) and the average Q-LV at the optimal LV endocardial pacing site 157 ms (128-176 ms), resulting in a Q-LV/QRS ratio of 93 %. The position of the original coronary sinus lead was apical in 3, anterolateral in 1 and mid-posterolateral in 1 patient (Fig. 2) .
In the remaining 4 patients, the average AHR at the optimal endocardial position increased < 15 %, with an average of 7.3 % (1.7-9.9 %). The average QRS width in these patients was 176 ms (149-209 ms) and the average Q-LV 136 ms (100-174 ms), resulting in a Q-LV/QRS ratio of 83 %. The coronary sinus lead position was posterolateral in all 4 patients.
Non-responders with non-LBBB Four patients did not have LBBB. Of these, only one patient with RBBB, combined with left anterior hemiblock, showed an increase in the AHR, from − 9.1 % (apical coronary sinus position) to 25.8 % at an endocardial basal posterolateral position. Two of the other patients had an RBBB pattern (Fig. 3) ; one had a non-specific intraventricular conduction tion of the coronary sinus lead, the AHR could be increased during LV endocardial pacing from 19.7-66 % and we considered the increase sufficient to justify the upgrade to LV endocardial pacing (Fig. 1) .
In the 19 patients with an AHR from the implanted system < 15 %, 9 patients had an increase in AHR above the 15 % limit. The results of the total group of 24 patients showed a positive response in 11 patients with an apical lead position in 7, anterolateral in 2 and mid-posterolateral in 2 patients.
A negative response of endocardial pacing was observed in 13 patients with a basal posterolateral lead position in 3, mid-posterolateral in 8 and apical in 2 patients.
Non-responders with LBBB
In 5 out of the 9 acute haemodynamic non-responders (AHR < 15 %) with LBBB, the AHR could be increased above the 15 % level by LV endocardial pacing. The average AHR with the coronary sinus system was 9.6 % (5.8-14.9 %) and at the LV endocardial optimal position 25.8 % (19.0-34.3 %). The average QRS width in these patients was Baseline LVdP/dtmax LVdP/dtmax with intrinsic rhythm or right ventricular pacing, AHR CS lead acute haemodynamic response from the coronary sinus (CS) lead expressed as percentage rise in LVdP/dtmax from baseline, AHR CS level endo acute haemodynamic response at an endocardial location opposite the CS lead, LV endo optimal position anatomic site with the highest AHR, AHR LV endo Acute haemodynamic response from the optimal endocardial position. Grey shaded patients have an AHR from the CS lead ώ 15 % and are considered haemodynamic responders, PL-bas basal posterolateral, PL-mid mid-posterolateral, RVP right ventricular pacing. sinus leads were in an apical, anterolateral and mid-posterolateral position. In the other 3 patients the average AHR increased from 2.9 % (1.1-4.0 %) to 9.7 % (7.8-11.4 %). In 2 patients the coronary sinus lead was in a mid-posterolateral position, one in an apical position. Individual details are summarised in Table 2 and a flow chart overview in Fig. 4. delay with a QRS complex of 175 ms. The coronary sinus lead position was mid-posterolateral in 2 and apical in 1 patient.
Non-responders with right ventricular pacing
Three out of the 6 patients with RV pacing became haemodynamic responders (LV dP/dtmax from average 9.7 %, (9.3-12.7 %) increased to 21.8 % (16.6-24.8 %)). Coronary Table 3 .
Follow-up
Ten patients were considered possible candidates for LV endocardial pacing: 9 patients in whom a rise in LVdP/ dtmax ≥ 15 % level was only obtained by endocardial pacing, and the patient that showed a substantial additional rise in AHR with LV pacing compared with coronary sinus pacing (patient 15). One patient died from progressive heart failure before the endocardial implant could be performed.
Of the remaining 9 patients, and after deliberation with the patients about the possible benefits and risks, 5 of them finally agreed to LV endocardial implant at the optimal LV site as indicated from the acute study [9] . All five patients improved clinically with a reduction of at least 1 class in the NYHA score after 6 months of follow-up. Two patients with a positive response in the temporary study refrained from implantation of an LV endocardial lead.
One patient with a positive AHR from endocardial pacing also improved significantly after changing stimulation from the distal to the proximal electrode with a more basal position, and became a clinical responder after optimisation of the atrioventricular and interventricular interval.
In one patient, the deterioration of his condition after initial improvement proved to be the result of a blunted chronotropic response after increasing beta-blocker dosage following an episode of atrial fibrillation resulting in an
Epicardial vs endocardial haemodynamics
When pacing endocardially, opposite the epicardial coronary sinus lead, we found that LVdP/dtmax did not differ significantly for any of the patients: LVdP/dtmax from the coronary sinus averaged 1046 ± 292 mmHg/s vs. 1068 ± 296 mmHg/s from the corresponding LV endocardial site (p = 0.37).
Haemodynamics during endocardial pacing from different locations
We found that basal or mid-posterolateral segments had the highest AHR of the tested endocardial sites in all 14 patients who showed an AHR ≥ 15 % rise in LVdP/dtmax compared with baseline. Because either the basal or mid-posterolateral segment had the highest AHR, we also calculated the combined best results from basal posterolateral and midposterolateral (PL-best). PL-best had a rise to 30.2 ± 13.6 % in LVdP/dtmax, basal posterolateral 27.7 ± 15.2 %, midposterolateral 24.6 ± 12.6 %, LV apical 14.8 ± 9.1 % and LV septal 17.0 ± 11.2 %.
Haemodynamic effect and Q-LV interval
We also found that in 12 out of the 14 patients (85 %) with an AHR ≥ 15 %, the LV endocardial site with the longest time interval between the onset of the QRS complex and LV sensing (Q-LV interval) resulted in the best haemodynamic response [10] . The average QRS width was 133 ± 22 ms (range 120-205 ms) and average Q-LV interval 155 ± 26 ms 27.7 ± 15.2 24.6 ± 12.6 14.8 ± 9.1 17.1 ± 11.2 173 ± 22 155 ± 26 AHR Acute haemodynamic response expressed as the percentage rise in LVdP/dt from baseline, PL-best best result from either basal posterolateral (PL-bas) or mid-posterolateral (PL-mid) region, Max Q-LV longest interval measured between onset of the QRS complex and intrinsic activation at the LV electrode. Location of this electrode is indicated in last column. Grey shaded area indicates 2 patient in whom the longest Q-LV interval did not correspond with the best haemodynamic response.
haemodynamic response can still be significantly improved in the presence of an anterior or apical lead position [10] . A similar discrepancy is found with echocardiography as the observed presence or absence of decrease in LV end-diastolic volume or end-systolic volume and clinical response does not always correlate [17] .
To err on the safe side, we therefore proceeded to a permanent LV endocardial implantation when the final increase in AHR was at least 25 %. There was no clinical evidence for the choice of this percentage.
The best AHR correlates well with the longest time interval between onset QRS and LV sensing in relation to the QRS width in the individual patient [18] .
The results of the group of patients with non-LBBB are in line with what could be expected according to the literature [19] . The absence of response correlated well to the lack of conduction delay in any of the LV segments on the intracardiac LV electrogram. The only responder to endocardial pacing in this group had a significant LV conduction delay due to the left anterior hemiblock that accompanied RBBB. It is therefore questionable if one should proceed with endocardial mapping in this cohort of patients given the disappointing results [19] .
Conclusions
This observational study showed that a temporary acute haemodynamic study could be useful in non-responders to establish the chance of improvement with alternative pacing sites before embarking on complex procedures as endocardial LV pacing. It remains, however, uncertain what the optimal cut-off value for increase in LVdP/dtmax is before the improvement justifies intervention. The longest Q-LV interval is a reliable indicator for the optimal electrode position in the individual patient.
Endocardial pacing opposite epicardial sites does not show acute haemodynamic improvement, so epicardial pacing at the optimal site may be a good alternative for endocardial LV lead placement. Although all patients who had a LV endocardial system implanted after a positive AHR improved clinically, larger randomised series are necessary to justify this technique before definitive conclusions can be drawn. Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
inappropriate ICD shock. Activation of sensor driven pacing restored his clinical status to the former level.
Discussion
This observational study showed that endocardial LV pacing, guided by acute haemodynamic studies, could improve clinical outcome in patients not responding to conventional CRT. It also demonstrated the importance of lead location, as the clinical response improved with a posterolateral position of the lead instead of the original apical or anterolateral lead location. Conversely, none of the patients who already had a coronary sinus lead in a posterolateral position improved sufficiently with endocardial pacing at any site during the acute haemodynamic study to justify endocardial lead implant. This is in line with the MADIT-CRT trial, where the apical and anterior positions of the LV lead had a lower clinical response [10] .
Noteworthy, and similar to what has previously been reported, endocardial pacing opposite the coronary sinus pacing site did not improve the AHR in our study [11] [12] [13] . This is in contrast with animal experiments that show significantly better haemodynamic results with endocardial vs. epicardial pacing at the same location [14] . There is no clear single cause for this difference and it is most probably related to variance in the anatomical and electrophysiological substrate. Besides this, in animal experience the lead configuration guarantees an exact position of the endocardial lead opposite to the epicardial position; this in contrast with human studies in which the endocardial lead is placed as close as possible to its epicardial counterpart.
Therefore, although not examined in this and other studies, one either might speculate that epicardial pacing opposite the optimal endocardial sites, via the coronary sinus or surgically by thoracoscopy, might have resulted in similar benefits. If feasible, this might be a good alternative to avoid the uncertainty of thromboembolic complications with LV endocardial pacing [15] .
Our observational study also showed some limitations in the use of acute haemodynamic studies to predict clinical outcome. First, five clinical non-responders showed a clear AHR according to the accepted criteria (even with the higher than usual cut-off value of 15 % increase in LVdP/dtmax to exclude borderline cases) but failed to respond clinically [16] .
Still, when a substantial further increase in LVdP/dtmax from endocardial pacing at a posterolateral position compared with the apical coronary sinus lead (66 vs. 19.7 %) was obtained in one patient, endocardial lead implantation resulted in a positive clinical response. This illustrates the limitation of cut-off values in CRT studies of the 15 % level as surrogate for differentiating between clinical response and non-response, and that what is considered a positive
